Oncology
A novel inhibitor of kinase insert domain-containing receptor fights tumors
Published in Cancer Weekly, March 16th, 2004
According to recent research from the United States, "a strategy for antagonizing vascular endothelial growth factor (VEGF)-induced angiogenesis is to inhibit the kinase activity of its receptor, kinase insert domain-containing receptor (KDR), the first committed and perhaps the last unique step in the VEGF signaling cascade."
"We synthesized a novel ATP-competitive KDR tyrosine kinase inhibitor that potently suppresses human and mouse KDR activity in enzyme (IC50 = 7.8 - 19.5 nM) and cell-based assays (IC50 = 8 nM). The compound was bioavailable in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-03-16)
More Articles from Cancer Weekly
- Breast Cancer Prognosis
Expression of IGF-I receptor indicates poor prognosis for breast cancer - Breast Cancer Therapy
Anastrozole is alternative to tamoxifen for women with early breast cancer - Acute Myelogenous Leukemia
Antigens show promise for development of acute myeloid leukemia immunotherapy - Breast Cancer
Transgenic mouse model for breast cancer developed - Breast Cancer Therapy
Regulatory nodes coordinating signaling are potential breast cancer targets - Prostate Cancer Risk Factor
Insulin-like growth factor linked to prostate cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
